Databricks said annualized revenue has jumped more than 80% from a year earlier and now sits at $6.9 billion, up from a figure of $5.4 billion in the fiscal fourth quarter. While Databricks is ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Databricks CEO and co-founder Ali Ghodsi asserts that enterprise AI's true bottleneck lies ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...